Pituitary Gland Disease

Categories: Endocrine diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pituitary Gland Disease

MalaCards integrated aliases for Pituitary Gland Disease:

Name: Pituitary Gland Disease 11 14 16
Pituitary Dysfunction 53 71
Pituitary Diseases 53 71
Pituitary Disease 11 75
Pituitary Deficiency 58
Pituitary Disorders 41


Orphanet: 58  
Rare endocrine diseases

External Ids:

Disease Ontology 11 DOID:53
ICD9CM 34 253.1
ICD10 31 E23.6 E23.7
ICD10 via Orphanet 32 E23.0
UMLS via Orphanet 72 C0020635
Orphanet 58 ORPHA101957
UMLS 71 C0029493 C0032002 C0281947

Summaries for Pituitary Gland Disease

MedlinePlus: 41 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. With pituitary disorders, you often have too much or too little of one of your hormones. Injuries can cause pituitary disorders, but the most common cause is a pituitary tumor.

MalaCards based summary: Pituitary Gland Disease, also known as pituitary dysfunction, is related to inappropriate adh syndrome and optic nerve hypoplasia, bilateral, and has symptoms including tremor, back pain and headache. An important gene associated with Pituitary Gland Disease is PRL (Prolactin), and among its related pathways/superpathways are Signal Transduction and Class A/1 (Rhodopsin-like receptors). The drugs Prednisone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include pituitary gland, pituitary and brain, and related phenotypes are nervous system and homeostasis/metabolism

Disease Ontology: 11 An endocrine system disease that is located in the pituitary gland.

Wikipedia: 75 A pituitary disease is a disorder primarily affecting the pituitary... more...

Related Diseases for Pituitary Gland Disease

Diseases related to Pituitary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 539)
# Related Disease Score Top Affiliating Genes
1 inappropriate adh syndrome 32.3 PRL POMC CRH AVP
2 optic nerve hypoplasia, bilateral 32.2 POMC HESX1 AVP
3 pituitary cancer 32.2 SST PRL POMC MEN1 MEG8 IGF1
4 hypothyroidism, central, with testicular enlargement 32.1 TRH PROP1 PRL POU1F1
5 central diabetes insipidus 31.9 TRH PRL POMC IGF1 GNRH1 GH1
6 prader-willi syndrome 31.9 TRH PRL POMC INS IGF1 GNRH1
7 pituitary apoplexy 31.8 TRH SST PRL POMC INS IGF1
8 hypopituitarism 31.7 TRH RNU4ATAC PROP1 PRL POU1F1 POMC
9 pituitary tumors 31.1 SST PROP1 PRL MEN1 IGF1 GH1
10 pituitary-dependent cushing's disease 30.9 TRH SST PRL POMC GHRH GH1
11 premature ovarian failure 7 30.9 POMC GH1 CRH
12 acromegaly 30.9 TRH SST PRL POMC MEN1 INS
13 adenoma 30.8 TRH SST PRL POU1F1 POMC MEN1
14 pituitary adenoma 30.8 TRH SST PRL POU1F1 POMC MEN1
15 hypoglycemia 30.7 TRH SST PRL POMC INS IGF1
16 conn's syndrome 30.7 TRH SST PRL POMC MEN1 INS
17 multiple endocrine neoplasia 30.7 SST PRL POMC MEN1
18 hyperprolactinemia 30.7 TRH SST PRL POMC INS IGF1
19 diabetes insipidus 30.6 PRL POMC INS GH1 CRH AVP
20 pituitary adenoma 1, multiple types 30.6 SST PRL MEN1 IGF1 GH1
21 insulin-like growth factor i 30.6 SST PRL INS IGF1 GHRH GH1
22 multiple endocrine neoplasia, type i 30.6 SST PRL POMC MEN1 INS GHRH
23 prolactinoma 30.6 TRH SST PRL POU1F1 POMC MEN1
24 graves disease 1 30.6 TRH POMC INS
25 polycystic ovary syndrome 30.6 PRL POMC INS IGF1 GNRH1 GH1
26 holoprosencephaly 30.6 PROP1 POU1F1 LHX3 HESX1
27 adult syndrome 30.5 POMC INS IGF1 CRH
28 hypothyroidism, congenital, nongoitrous, 4 30.5 PROP1 PRL POU1F1 POMC IGF1 GH1
29 adrenal adenoma 30.5 POMC MEN1 CRH
30 hormone producing pituitary cancer 30.5 SST PRL POMC MEN1 IGF1 GHRH
31 hypogonadism 30.4 PROP1 PRL POMC INS IGF1 GNRH1
32 hyperthyroidism 30.4 TRH SST PRL POMC INS IGF1
33 amenorrhea 30.4 TRH PRL POMC INS IGF1 GNRH1
34 anorexia nervosa 30.4 PRL POMC INS IGF1 GHRH GH1
35 body mass index quantitative trait locus 11 30.3 TRH PRL POMC INS IGF1 GNRH1
36 combined pituitary hormone deficiencies, genetic forms 30.3 PROP1 POU1F1 HESX1
37 craniopharyngioma 30.3 TRH PROP1 PRL POU1F1 INS IGF1
38 pituitary hormone deficiency, combined or isolated, 1 30.3 POU1F1 HESX1
39 gynecomastia 30.3 PRL POMC GNRH1
40 central precocious puberty 30.3 POMC IGF1 GNRH1
41 hypogonadotropic hypogonadism 30.3 PROP1 PRL POMC INS IGF1 HESX1
42 mccune-albright syndrome 30.3 SST PRL POMC MEN1 IGF1 GHRH
43 apnea, obstructive sleep 30.3 POMC INS IGF1
44 galactorrhea 30.3 PRL IGF1
45 intracranial hypertension 30.3 PRL POMC AVP
46 cranial nerve palsy 30.3 PRL POMC AVP
47 suprasellar meningioma 30.2 TRH POMC AVP
48 hypothyroidism 30.2 TRH SST PROP1 PRL POU1F1 POMC
49 sleep disorder 30.2 POMC INS IGF1 CRH
50 pituitary hormone deficiency, combined, 2 30.2 TRH PROP1 PRL POU1F1 POMC LHX3

Graphical network of the top 20 diseases related to Pituitary Gland Disease:

Diseases related to Pituitary Gland Disease

Symptoms & Phenotypes for Pituitary Gland Disease

UMLS symptoms related to Pituitary Gland Disease:

tremor; back pain; headache; syncope; pain; chronic pain; sciatica; seizures; vertigo/dizziness; sleeplessness

MGI Mouse Phenotypes related to Pituitary Gland Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.36 AVP CRH GH1 GHRH GNRH1 HESX1
2 homeostasis/metabolism MP:0005376 10.2 AVP CRH GH1 GHRH GNRH1 IGF1
3 growth/size/body region MP:0005378 10.1 CRH GH1 GHRH GNRH1 HESX1 IGF1
4 renal/urinary system MP:0005367 10.03 AVP CRH GH1 GNRH1 IGF1 INS
5 liver/biliary system MP:0005370 10.01 CRH GH1 GHRH GNRH1 INS MEN1
6 endocrine/exocrine gland MP:0005379 10 CRH GH1 GHRH GNRH1 HESX1 IGF1
7 adipose tissue MP:0005375 9.91 CRH GH1 GHRH IGF1 INS POMC
8 immune system MP:0005387 9.73 AVP CRH GH1 GHRH GNRH1 IGF1
9 reproductive system MP:0005389 9.32 GH1 GHRH GNRH1 IGF1 INS LHX3

Drugs & Therapeutics for Pituitary Gland Disease

Drugs for Pituitary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
Acetaminophen Approved Phase 4 103-90-2 1983
Ibuprofen Approved Phase 4 15687-27-1 3672
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Cefuroxime Approved Phase 4 55268-75-2 5479529
Cefdinir Approved Phase 4 91832-40-5 6915944
Cefazolin Approved Phase 4 25953-19-9 33255
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
Cabergoline Approved Phase 4 81409-90-7 54746
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
36 Protective Agents Phase 4
37 Antineoplastic Agents, Hormonal Phase 4
38 Gastrointestinal Agents Phase 4
39 Antirheumatic Agents Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4
42 Analgesics, Opioid Phase 4
43 Narcotics Phase 4
44 Neuroprotective Agents Phase 4
Triamcinolone hexacetonide Phase 4
Triamcinolone diacetate Phase 4
Triamcinolone Acetonide Phase 4 6436
Methylprednisolone Acetate Phase 4 584547
49 Immunosuppressive Agents Phase 4
50 Immunologic Factors Phase 4

Interventional clinical trials:

(show top 50) (show all 176)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
3 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
4 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
5 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
6 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor;IV Placebo
7 A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
8 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
9 Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study) Recruiting NCT04897802 Phase 4 Experimental: GLP1-RA (exenatide) administration;Control: Placebo administration
10 Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept Physiopathological Study (CRH Study) Recruiting NCT04902235 Phase 4 Experimental: CRH administration;Control: Placebo administration
11 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
12 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
13 The Effects of Infraorbital Nerve Block With Dexmedetomidine Added to Bupivacaine on Fentanyl Requirement During Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor: Prospective Randomized Double Blinded Control Study Not yet recruiting NCT04785222 Phase 4 dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
14 The Effect of Semaglutide on Pituitary Function Not yet recruiting NCT04865744 Phase 4 Semaglutide 7 MG Oral Tablet;Placebo
15 The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China Unknown status NCT04326374 Phase 3 TransCon hGH;daily hGH
16 Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles Unknown status NCT03044756 Phase 2, Phase 3 Omit Citrotide 0.25 dose on the day of triggering of ovulation
17 The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration Unknown status NCT00386022 Phase 2, Phase 3 GnRH;NAL-GLU GnRH antagonist;Estrogen patch
18 Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa Completed NCT01653743 Phase 3 MSJ-0011;urinary hCG (u-hCG);Follitropin alpha
19 fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD Completed NCT03305016 Phase 3 TransCon hGH
20 A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD) Completed NCT02781727 Phase 3 Once weekly subcutaneous injection of TransCon hGH;Once daily subcutaneous injection of Genotropin
21 Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method Completed NCT00234533 Phase 3 Somatropin (rDNA origin)
22 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
23 A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency Completed NCT00596037 Phase 3 Growth hormone - LB03002
24 A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills Completed NCT00117273 Phase 3 Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)];Seasonique (LNG/EE and EE);Portia (LNG/EE)
25 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
26 Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
27 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency. Completed NCT00294619 Phase 3 growth hormone
28 Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study Completed NCT01185782 Phase 3 Gonalef® (Follitropin alfa);Purified pituitary gonadotropin (Fertinorm-P®)
29 An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Recruiting NCT03882034 Phase 3 Pegvisomant
30 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
31 enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial Active, not recruiting NCT03344458 Phase 3 TransCon hGH
32 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
33 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
34 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Terminated NCT02419664 Phase 3 Gallium-68 DOTATOC PET
35 A Multicentre, Prospective, Open Study to Describe the Effects of rhLH Supplement in Women With Hyporesponse to rFSH After Pituitary Downregulation. Unknown status NCT01029470 Phase 2 Luveris
36 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
37 A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism Completed NCT01673646 Phase 2 Pasireotide LAR
38 Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
39 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
40 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
41 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab
42 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
43 Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery Not yet recruiting NCT05005715 Phase 2 Dexmedetomidine;normal saline
44 Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC Terminated NCT02749227 Phase 2 Pasireotide LAR
45 An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
46 Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
47 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Terminated NCT03930771 Phase 2 Capecitabine;Temozolomide
48 Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas Terminated NCT01444209 Phase 2
49 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Withdrawn NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
50 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1

Search NIH Clinical Center for Pituitary Gland Disease

Genetic Tests for Pituitary Gland Disease

Anatomical Context for Pituitary Gland Disease

Organs/tissues related to Pituitary Gland Disease:

FMA: Pituitary Gland
MalaCards : Pituitary, Brain, Hypothalamus, Thyroid, Spinal Cord, Heart, Liver

Publications for Pituitary Gland Disease

Articles related to Pituitary Gland Disease:

(show top 50) (show all 2684)
# Title Authors PMID Year
Clinical characteristics of rheumatic disease-associated hypophysitis: A case series and review of literature. 62 41
36316923 2022
Cellular interactions in the pituitary stem cell niche. 41
36451046 2022
Pseudocapsule and pseudocapsule-based extracapsular resection in pituitary neuroendocrine tumors. 41
36465639 2022
Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. 53 62
20207728 2010
Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism. 53 62
19549748 2009
Clinical insights into the safety and utility of the insulin tolerance test (ITT) in the assessment of the hypothalamo-pituitary-adrenal axis. 53 62
18346212 2008
Dual bronchial carcinoids and Cushing's syndrome with a paradoxical response to dexamethasone and a false positive outcome of inferior petrosal sinus sampling. 53 62
18625689 2008
Appropriate use of stimulation tests and insulin-like growth factor-I in obesity. 53 62
19020381 2008
Hypopituitarism and HIV-infection: a new comorbidity in the HAART era? 53 62
19020383 2008
Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism. 53 62
18493103 2008
Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. 53 62
17984238 2007
IGF-I measurements in the diagnosis of adult growth hormone deficiency. 53 62
17429593 2007
Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury. 53 62
17405254 2006
Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. 53 62
16882751 2006
Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease. 53 62
15952410 2005
Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index. 53 62
15328071 2005
Do all adults with growth hormone deficiency require growth hormone treatment? 53 62
14572166 2003
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. 53 62
11836268 2002
Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. 53 62
11748154 2001
Fetal antigen 1 in healthy adults and patients with pituitary disease: relation to physiological, pathological, and pharmacological GH levels. 53 62
11701723 2001
Optimizing gh therapy in adults and children. 53 62
11493578 2001
LHX3 transcription factor mutations associated with combined pituitary hormone deficiency impair the activation of pituitary target genes. 53 62
11255008 2001
The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients. 53 62
11167924 2001
Biochemical and genetic characterization of the porcine Prophet of Pit-1 pituitary transcription factor. 53 62
11064154 2000
Galactorrhea may be clue to serious problems. Patients deserve a thorough workup. 53 62
10887453 2000
Analysis of the human LHX3 neuroendocrine transcription factor gene and mapping to the subtelomeric region of chromosome 9. 53 62
10717474 2000
Comment on comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. 53 62
10443706 1999
Evaluation of adrenal function in patients with hypothalamic and pituitary disorders: comparison of serum cortisol, urinary free cortisol and the human-corticotrophin releasing hormone test with the insulin tolerance test. 53 62
10468905 1999
Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. 53 62
10084558 1999
Comments on the comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. 53 62
9851806 1998
Commentary to the article: comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. 53 62
9851808 1998
Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. 53 62
9589655 1998
Adult vs childhood onset GHD: is there a real clinical difference? 53 62
10993586 1998
The Gordon Wilson Lecture. Growth hormone replacement in adults and other uses. 53 62
9601130 1998
Comparison of tests of stress-released cortisol secretion in pituitary disease. 53 62
8881444 1996
Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. 53 62
8675591 1996
IGF-1 and IGFBP-3 screening for disorders of growth hormone secretion. 53 62
8657365 1996
A comparison between short ACTH and insulin stress tests for assessing hypothalamo-pituitary-adrenal function. 53 62
8706316 1996
Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. 53 62
8586028 1995
The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. 53 62
7714104 1995
[A case of primary hypothyroidism with pituitary enlargement and abnormal secretion of growth hormone and prolactin]. 53 62
7750626 1995
High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. 53 62
7921222 1994
Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (IGFBP)-1 levels following acute hypoglycaemia. 53 62
7687525 1993
Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. 53 62
8097480 1993
Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. 53 62
1479002 1992
Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. 53 62
1320051 1992
Growth hormone specific stimulation of mitosis by size-fractionated serum from patients with growth hormone insufficiency: a study on the rat lymphoma cell line, Nb2. 53 62
1897328 1991
Corticotropin-releasing hormone testing in pituitary disease. 53 62
1652435 1991
An apparent cluster of congenital hypopituitarism in central Massachusetts: magnetic resonance imaging and hormonal studies. 53 62
1846002 1991
Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement. 53 62
2128941 1990

Variations for Pituitary Gland Disease

Expression for Pituitary Gland Disease

Search GEO for disease gene expression data for Pituitary Gland Disease.

Pathways for Pituitary Gland Disease

GO Terms for Pituitary Gland Disease

Cellular components related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.16 SST PRL POMC INS IGF1 GNRH1
2 extracellular region GO:0005576 10 AVP CRH GH1 GHRH GNRH1 IGF1
3 endosome lumen GO:0031904 9.1 PRL INS GH1

Biological processes related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ERK1 and ERK2 cascade GO:0070371 9.85 IGF1 HESX1 AVP
2 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.63 IGF1 GHRH GH1
3 somatotropin secreting cell differentiation GO:0060126 9.62 PROP1 LHX3
4 pituitary gland development GO:0021983 9.56 PROP1 LHX3 HESX1
5 cell-cell signaling GO:0007267 9.47 TRH SST POMC INS GNRH1 GHRH
6 adenohypophysis development GO:0021984 9.35 PROP1 POU1F1 GHRH

Molecular functions related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.63 GHRH CRH AVP
2 hormone activity GO:0005179 9.6 TRH SST PRL POMC INS IGF1
3 prolactin receptor binding GO:0005148 9.26 PRL GH1

Sources for Pituitary Gland Disease

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....